Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352298 | 0.95 | HTT (0.38) | ABCB1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL4347480 | 0.90 | MAOA (0.44) | ABCB1ALDH1A1MAPTHTT | |
| SCHEMBL4352403 | 0.90 | ABCB1 (0.39) | ABCB1ALDH1A1MAPTHTTPOLB | |
| SCHEMBL6051065 | 0.88 | MAOB (0.42) | ABCB1ALDH1A1HTTRAB9A | |
| SCHEMBL6051143 | 0.84 | ABCB1 (0.36) | ABCB1ALDH1A1MAPTHTTPOLB | |
| SCHEMBL6436803 | 0.83 | ADAMTS4 (0.44) | ABCB1RAB9A | |
| SCHEMBL6051171 | 0.82 | ALDH1A1 (0.41) | ALDH1A1MAPTHTTRAB9AADRA1D | |
| SCHEMBL6913199 | 0.82 | ADAMTS4 (0.46) | ABCB1ALDH1A1HTTRAB9A | |
| SCHEMBL4353782 | 0.82 | ABCB1 (0.55) | ABCB1ADRA1A | |
| SCHEMBL4353788 | 0.82 | ABCB1 (0.55) | ABCB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | ITGB3 4528/4885ITGA2B 4690/4885ABCB1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.